全文获取类型
收费全文 | 112412篇 |
免费 | 10090篇 |
国内免费 | 3478篇 |
专业分类
耳鼻咽喉 | 412篇 |
儿科学 | 1579篇 |
妇产科学 | 1373篇 |
基础医学 | 7733篇 |
口腔科学 | 1351篇 |
临床医学 | 11356篇 |
内科学 | 16494篇 |
皮肤病学 | 1411篇 |
神经病学 | 5481篇 |
特种医学 | 1723篇 |
外国民族医学 | 15篇 |
外科学 | 4575篇 |
综合类 | 15170篇 |
现状与发展 | 11篇 |
一般理论 | 5篇 |
预防医学 | 9236篇 |
眼科学 | 877篇 |
药学 | 34787篇 |
43篇 | |
中国医学 | 4431篇 |
肿瘤学 | 7917篇 |
出版年
2024年 | 99篇 |
2023年 | 1566篇 |
2022年 | 2224篇 |
2021年 | 4052篇 |
2020年 | 3905篇 |
2019年 | 3802篇 |
2018年 | 3973篇 |
2017年 | 4100篇 |
2016年 | 4163篇 |
2015年 | 4288篇 |
2014年 | 7496篇 |
2013年 | 10949篇 |
2012年 | 7518篇 |
2011年 | 7990篇 |
2010年 | 6288篇 |
2009年 | 5825篇 |
2008年 | 5806篇 |
2007年 | 5713篇 |
2006年 | 5091篇 |
2005年 | 4420篇 |
2004年 | 3724篇 |
2003年 | 3153篇 |
2002年 | 2437篇 |
2001年 | 2308篇 |
2000年 | 1807篇 |
1999年 | 1605篇 |
1998年 | 1274篇 |
1997年 | 1230篇 |
1996年 | 1050篇 |
1995年 | 964篇 |
1994年 | 846篇 |
1993年 | 700篇 |
1992年 | 745篇 |
1991年 | 640篇 |
1990年 | 512篇 |
1989年 | 428篇 |
1988年 | 405篇 |
1987年 | 394篇 |
1986年 | 290篇 |
1985年 | 378篇 |
1984年 | 307篇 |
1983年 | 214篇 |
1982年 | 242篇 |
1981年 | 179篇 |
1980年 | 144篇 |
1979年 | 134篇 |
1978年 | 115篇 |
1977年 | 112篇 |
1976年 | 107篇 |
1975年 | 86篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
83.
84.
《慢性疾病与转化医学(英文)》2019,5(4):258-266
Despite tremendous efforts to fight cancer, it remains a major public health problem and a leading cause of death worldwide. With increased knowledge of cancer pathways and improved technological platforms, precision therapeutics that specifically target aberrant cancer pathways have improved patient outcomes. Nevertheless, a primary cause of unsuccessful cancer therapy remains cancer drug resistance. In this review, we summarize the broad classes of resistance to cancer therapy, particularly pharmacokinetics, the tumor microenvironment, and drug resistance mechanisms. Furthermore, we describe how bacterial-mediated cancer therapy, a bygone mode of treatment, has been revitalized by synthetic biology and is uniquely suited to address the primary resistance mechanisms that confound traditional therapies. Through genetic engineering, we discuss how bacteria can be potent anticancer agents given their tumor targeting potential, anti-tumor activity, safety, and coordinated delivery of anti-cancer drugs. 相似文献
85.
目的 了解我国医院高血压合理用药文献的研究趋势和热点,为提出促进高血压合理用药的相关措施提供参考。方法 检索2010—2017年中国知网数据库、万方数据库、维普数据库收录的高血压合理用药的相关文献,运用书目信息共现分析系统(BICOMB)2.0提取关键词、年份及相应文献量、期刊、作者及机构等参量进行文献计量学分析,并构建高频关键词词篇矩阵;将该词篇矩阵导入SPSS21.0软件进行系统聚类分析;利用图形聚类工具包(gCLUTO)1.0版对词篇矩阵进行词篇共现分析和双聚类可视化分析。结果 从知网、万方、维普三大数据库共检索到高血压合理用药相关文献1 010篇;从年发文量来看,高血压合理用药问题一直是研究热点;从期刊分布来看,高血压合理用药相关文献分布于262种期刊,高血压合理用药问题受到期刊界的广泛关注;从发文作者来看,我国还未形成高血压合理用药研究的核心力量;从单位分布来看,发文机构分散,多数为医院;高频关键词聚焦于“抗高血压药物/降压药、合理用药、高血压、用药分析”等。结论 我国目前对于高血压合理用药的研究多为对单个医院高血压患者用药合理性评价或是对抗高血压药物临床应用的分析,该领域的研究仍需从简单定性分析转向多地区、多层次、大样本的定量分析,以更好地促进高血压合理用药。 相似文献
86.
Uday Yanamandra Prateek Deo Kamal Kant Sahu Ram Vasudevan Nampoothiri Nalini Gupta Anusree Prabhakaran Deb Prasad Dhibhar Alka Khadwal Gaurav Prakash Man Upadesh Singh Sachdeva Deepesh Lad Neelam Varma Subhash Varma Pankaj Malhotra 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):183-189.e1
Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献87.
血吸虫病是一种严重危害人类健康、影响社会经济发展的重大传染病,为全球公共卫生负担和危害最严重的被忽视的热带病之一。吡喹酮是20世纪70年代研制出的一种高效、低毒、价廉的广谱抗蠕虫口服药,为世界卫生组织(WHO)推荐的抗血吸虫的首选药物。吡喹酮在血吸虫病流行区现场大规模反复使用已超过40年,血吸虫是否会对吡喹酮产生抗药性引起国际社会极大担忧,为学术界关注的热点科学问题。针对血吸虫病防治中这一重大需求,自1996年起, 在国家科技支撑计划、国家自然科学基金、江苏省自然科学基金等项目基金资助下,我们在血吸虫病流行区现场和实验室,对血吸虫在吡喹酮药物的压力是否会产生抗药性、抗性虫株的生物学特性、抗性的检测、吡喹酮抗性的交叉抗药性及抗药性的预防和控制等科学问题进行较为系统的研究,本文就其研究及其意义作一概述。 相似文献
88.
《Clinical therapeutics》2019,41(10):2162-2170
PurposeEravacycline is a broad-spectrum, intravenous fluorocycline antibiotic approved for the treatment of complicated intra-abdominal infections in adults. A 60-minute infusion is recommended for each infused dose. Compatibility data that may allow convenient Y-site administration of eravacycline with other parenteral medications are unavailable. We aimed to determine the physical compatibility of eravacycline with other intravenous medications by simulated Y-site administration.MethodsEravacycline was reconstituted according to published prescribing information and diluted with 0.9% sodium chloride to a concentration of 0.6 mg/mL. Simulated Y-site administration was performed by mixing 5 mL of eravacycline with an equal volume of 51 other intravenous medications, including crystalloid and carbohydrate hydration fluids and 20 antimicrobials. Secondary medications were assessed at the upper range of concentrations considered standard for intravenous infusion. Mixtures underwent visual inspection and turbidity measurement immediately on mixture and at 3 subsequent time points (30, 60, and 120 minutes after admixture), and pH was measured at 60 minutes for comparison with the baseline value of the secondary medication.FindingsEravacycline was physically compatible with 41 parenteral drugs (80%) by simulated Y-site administration. Incompatibility was observed with albumin, amiodarone hydrochloride, ceftaroline fosamil, colistimethate sodium, furosemide, meropenem, meropenem/vaborbactam, micafungin sodium, propofol, and sodium bicarbonate.ImplicationsEravacycline for injection was physically compatible with most parenteral medications assessed. Pharmacists and nurses should be knowledgeable of the observed incompatibilities with eravacycline to prevent the unintentional mixing of incompatible intravenous medications. 相似文献
89.
90.